TY - JOUR
T1 - Reduced GABAergic cortical inhibition in aging and depression
AU - Lissemore, Jennifer I.
AU - Bhandari, Apoorva
AU - Mulsant, Benoit H.
AU - Lenze, Eric J.
AU - Reynolds, Charles F.
AU - Karp, Jordan F.
AU - Rajji, Tarek K.
AU - Noda, Yoshihiro
AU - Zomorrodi, Reza
AU - Sibille, Etienne
AU - Daskalakis, Zafiris J.
AU - Blumberger, Daniel M.
N1 - Funding Information:
Competing interests: JIL, AB, and RZ report no biomedical interests or conflicts. BHM currently receives research funding from Brain Canada, the Centre for Addiction and Mental Health (CAMH) Foundation, the Canadian Institutes of Health Research (CIHR), Patient-Centered Outcomes Research Institute (PCORI), and the US National Institute of Health (NIH). During the last five years, he also received research support from Bristol-Myers Squibb (medications for a NIH-funded clinical trial), Eli-Lilly (medications for a NIH-funded clinical trial), and Pfizer (medications for a NIH-funded clinical trial). He directly own stocks of General Electric (less than $5000). EJL reports research funding (current/past) from Janssen, Alkermes, Acadia, Takeda, Lundbeck, Barnes Jewish Foundation, PCORI, and Taylor Family Institute for Innovative Psychiatric Research. CFR has received research support from the NIH, PCORI, the Center for Medicare and Medicaid Services, the American Foundation for Suicide Prevention, the Brain and Behavior Research Foundation, and the Commonwealth of Pennsylvania. Bristol Meyers Squib and Pfizer have provided pharmaceutical supplies for his NIH sponsored research. JFK received medication supplies from Indivior to support this investigator-initiated trial. He has also received medication supplies from Pfizer for investigator-initiated work. JFK receives research funding from NIH and PCORI. TKR receives research support from Brain Canada, Brain and Behavior Research Foundation, Canada Foundation for Innovation, the CIHR, Ontario Ministry of Health and Long-Term Care, Ontario Ministry of Research and Innovation, the NIH, and the W. Garfield Weston Foundation. YN has received equipment-in-kind support for an investigator-initiated study from Magventure Inc. He has also received research support from Otsuka Pharmaceutical Co., Ltd, Shionogi & Co., Ltd., and Meiji Seika Pharma Co., Ltd. YN has received research support from Meiji Yasuda Mental Health Foundation. ES has received support from NIH, CIHR, the Brain & Behavior Research Foundation (NARSAD) and the Campbell Family Mental Health Research Institute of CAMH. ES is co-inventor on a US provisional patent application that covers compounds modulating the function of GABA neurons. ZJD has received within the last 3 years both research and equipment in-kind support for an investigator-initiated study through Brainsway Inc and Magventure Inc. ZJD has also received monies for participation on an advisory board from Sunovion Inc. Finally, ZJD owns > $10,000 (CAD) in stock of Biogen Inc. DMB has received research support from CIHR, NIH, Brain Canada and the Temerty Family through the CAMH Foundation and the Campbell Research Institute. He receives research support and in-kind equipment support for an investigator-initiated study from Brainsway Ltd. and he is the site principal investigator for three sponsor-initiated studies for Brainsway Ltd. He also receives in-kind equipment support from Magventure for an investigator-initiated study. He receives medication supplies for an investigator-initiated trial from Indivior.
Funding Information:
This study was funded in part by a Brain and Behaviour Research Foundation New Investigator Award (DMB), the Canadian Institutes of Health Research and the National Institutes of Health (R01MH083643, R34MH101365). We would also like to acknowledge the Temerty Centre and the Canada Foundation for Innovation for providing TMS equipment.
Publisher Copyright:
© 2018, American College of Neuropsychopharmacology.
PY - 2018/10/1
Y1 - 2018/10/1
N2 - The neurobiology underlying depression in older adults is less extensively evaluated than in younger adults, despite the putative influence of aging on depression neuropathology. Studies using transcranial magnetic stimulation (TMS), a neurophysiological tool capable of probing inhibitory and excitatory cortical neurotransmission, have identified dysfunctional GABAergic inhibitory activity in younger adults with depression. However, GABAergic and glutamatergic cortical neurotransmission have not yet been studied in late-life depression (LLD). Here, we used single- and paired-pulse TMS to measure cortical inhibition and excitation in 92 LLD patients and 41 age-matched healthy controls. To differentiate the influence of age and depression, we also compared these TMS indices to those of 30 younger depressed adults and 30 age- and sex-matched younger healthy adults. LLD patients, older healthy adults, and younger depressed adults demonstrated significantly lower GABA A receptor-mediated cortical inhibition than younger healthy controls. By contrast, no significant differences in cortical inhibition were observed between older adults with and without depression. No significant differences in GABA B receptor-mediated inhibition or cortical excitation were found between the groups. Altogether, these findings suggest that reduced cortical inhibition may be associated with both advancing age and depression, which (i) supports the model of depression as a disease of accelerated aging, and (ii) prompts future investigation into diminished GABAergic neurotransmission in late-life as a biological predisposing factor to the development of depression. Given that cortical neurophysiology was similar in depressed and healthy older adults, future prospective studies need to establish the relative influence of age and depression on cortical inhibition deficits.
AB - The neurobiology underlying depression in older adults is less extensively evaluated than in younger adults, despite the putative influence of aging on depression neuropathology. Studies using transcranial magnetic stimulation (TMS), a neurophysiological tool capable of probing inhibitory and excitatory cortical neurotransmission, have identified dysfunctional GABAergic inhibitory activity in younger adults with depression. However, GABAergic and glutamatergic cortical neurotransmission have not yet been studied in late-life depression (LLD). Here, we used single- and paired-pulse TMS to measure cortical inhibition and excitation in 92 LLD patients and 41 age-matched healthy controls. To differentiate the influence of age and depression, we also compared these TMS indices to those of 30 younger depressed adults and 30 age- and sex-matched younger healthy adults. LLD patients, older healthy adults, and younger depressed adults demonstrated significantly lower GABA A receptor-mediated cortical inhibition than younger healthy controls. By contrast, no significant differences in cortical inhibition were observed between older adults with and without depression. No significant differences in GABA B receptor-mediated inhibition or cortical excitation were found between the groups. Altogether, these findings suggest that reduced cortical inhibition may be associated with both advancing age and depression, which (i) supports the model of depression as a disease of accelerated aging, and (ii) prompts future investigation into diminished GABAergic neurotransmission in late-life as a biological predisposing factor to the development of depression. Given that cortical neurophysiology was similar in depressed and healthy older adults, future prospective studies need to establish the relative influence of age and depression on cortical inhibition deficits.
UR - http://www.scopus.com/inward/record.url?scp=85047805702&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047805702&partnerID=8YFLogxK
U2 - 10.1038/s41386-018-0093-x
DO - 10.1038/s41386-018-0093-x
M3 - Article
C2 - 29849055
AN - SCOPUS:85047805702
SN - 0893-133X
VL - 43
SP - 2277
EP - 2284
JO - Neuropsychopharmacology
JF - Neuropsychopharmacology
IS - 11
ER -